Synthon B.v.

Synthon Biopharmaceuticals B.v.

Synthon Bct Technologies, LLC

Noven Therapeutics, LLC

Sython, B.v.

Frans Van Dalen

Jacobus Maria Lemmens

Frantisek Picha

Gerardus Joseph Andreas Ariaans

Franciscus Bernardus Gemma Benneker

Theodorus Hendricus Antonium Peters

Declan Thomas Nolan

Johannes Jan Platteeuw

Theodorus H A Peters

Korinde Annemarie Jansen

Farid Abedin Dorkoosh

Dennie J M Van Den Heuvel

Arlette Vanderheijden

Johannes J Platteeuw

Theororus Hendricus Antonius Peters

Gertruda Antonetta Philomina Van Helvoirt

Theororus Hendricus Peters

Jacohus Maria Lemmens

Gertruda Antonetta Van Helvoirt

Theodorus Hendricus Peters

Franciscus Bernardus Benneker

Lisa Karin Holmdahl

A monoclonal secretory IgA antibody, which binds to and neutralizes human TNF&#x3b1;. The secretory antibody is useful in treating a variety of inflammatory conditions in humans.

Anti-TNF alpha monoclonal secretory IgA antibodies and methods for treating inflammatory diseases

A monoclonal secretory IgA antibody, which binds to and neutralizes a human proinflammatory cytokine or which binds to and blocks a human proinflammatory cytokine receptor. The secretory IgA antibody is useful in treating a variety of inflammatory diseases in humans.

Monoclonal antibodies to human proinflammatory cytokines and methods for treating inflammatory diseases

A zolpidem tablet having modified release is designed as a tablet-in-tablet dosage form.

Zolpidem tablets

The invention relates to a compound, and pharmaceutically acceptable salts, having the formula I: wherein:

Crystalline paroxetine methane sulfonate

An amlodipine maleate pharmaceutical composition is provided with good stability when formulated with a pH within the range of 5.5 to 7, when measured as a 20 wt % aqueous slurry. The stability can also be aided by making the pharmaceutical composition from amlodipine maleate particles having an average particle size of greater than 20 microns, preferably greater than 100 microns.

Pharmaceutical compositions comprising amlodipine maleate

The invention relates to a compound, and pharmaceutically acceptable salts, having the formula I:wherein:

4-phenylpiperidine compounds

Paroxetine salt compositions having improved stability are formed by controlling the pH to 6.5 or less. The compositions can be made with the aide of water without significant coloration problems. The paroxetine salts include paroxetine hydrochloride salts but preferably use paroxetine sulfonate salts such as paroxetine methane sulfonate.

Paroxetine compositions and processes for making the same

Hypnotic pharmaceutical compositions are made from pellets and exhibit a modified release. Zolpidem or a pharmaceutically acceptable salt thereof is a typical hypnotic. The pellets are preferably spherical and exhibit a dissolution profile that includes 60% of the hypnotic agent being release from the pellet not earlier than 5 minutes from the start of a specified in vitro dissolution test. Although the modified release profile can include 50% of the hypnotic agent being released not earlier than 15 minutes after the start of the dissolution test, the pellet preferably does not contain a release rate controlling excipient or coating. Instead, microcrystalline cellulose and the active constitute the majority of the pellet, e.g. 90% or more. Spherical pellets are also made by a convenient method that is applicable to any pharmaceutically active agent.

Modified release formulations containing a hypnotic agent

A process for the production of simvastatin and its analogues that is efficient, economical and convenient involves the use of hydroxyl protected intermediates of formula (III) or (VII). These intermediates allow for direct alkylation of the butyrate side chain followed by deprotection and reformation of the lactone ring.

Process for producing simvastatin and/or its derivatives

A process for the production of simvastatin and its analogues that is efficient, economical and convenient involves the use of hydroxyl protected intermediates of formula (III) or (VII). These intermediates allow for direct alkylation of the butyrate side chain followed by deprotection and reformation of the lactone ring. R.sup.1 is hydrogen or methyl; R.sup.2 represents a straight or branched chain alkyl group having 1 to 8 carbon atoms, a cycloalkyl group having 3 to 7 carbon atoms, or an aralkyl group having 1 to 6 carbon atoms in the alkyl chain; R.sup.3 and R.sup.4 each independently represent an alkyl group, an ether group, a thioether group, an aryl group, an aralkyl group, an alkenyl group, a cyclic ether group, or a cyclic thioether group; and R.sup.5 and R.sup.6 each independently represent hydrogen, an alkyl group, an aryl group, an aralkyl group, an alkoxy group, or an ether group.

The invention relates to a compound, and pharmaceutically acceptable salts, having the formula I: ##STR1## wherein: R represents an alkyl or alkynyl group having 1-4 carbon atoms, or a phenyl group optionally substituted by C.sub.1-4 alkyl, alkylthio, alkoxy, halogen, nitro, acylamino, methylsulfonyl or methylenedioxy, or represents tetrahydronaphthyl,

Growing community of inventors

Nijmegen, Netherlands

Frans Van Dalen